News articles about Eleven Biotherapeutics (NASDAQ:EBIO) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eleven Biotherapeutics earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.9655496701726 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
NASDAQ EBIO traded up $0.07 on Monday, reaching $1.57. The company had a trading volume of 4,426,716 shares, compared to its average volume of 1,375,659. The company has a market cap of $64.66, a P/E ratio of -1.41 and a beta of 2.97. Eleven Biotherapeutics has a 12 month low of $0.62 and a 12 month high of $2.03.
A number of brokerages have issued reports on EBIO. HC Wainwright began coverage on shares of Eleven Biotherapeutics in a report on Tuesday, March 20th. They issued a “buy” rating and a $2.00 price target on the stock. ValuEngine upgraded shares of Eleven Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
ILLEGAL ACTIVITY WARNING: “Eleven Biotherapeutics (EBIO) Receives Daily News Sentiment Rating of 0.14” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/09/eleven-biotherapeutics-ebio-receives-daily-news-sentiment-rating-of-0-14.html.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc, a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.